9-cis retinoic acid induces insulin-like growth factor binding protein-3 through DR-8 retinoic acid responsive elements

Cancer Biology and Therapy

Volumn 5, Issue 6, 2006, Pages 586-592

  Yoon, Soo Chang ^a   Jae, Yong Cho ^a   Cho, Hyun A ^a   Hyung, Jung Kim ^a   Chang, Joon ^a   Chul, Min Ahn ^a   Sung, Kyu Kim ^a   Se, Kyu Kim ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

9 cis retinoic acids; Insulin like growth factor; Insulin like growth factor binding protein 3; Non small cell lung cancer; Retinoic acid receptor

Indexed keywords

ALITRETINOIN; RETINOIC ACID; RETINOIC ACID RECEPTOR BETA; SOMATOMEDIN BINDING PROTEIN 3;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS;

EID: 33745767094     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.6.2658     Document Type: Article

References (35)

1. Cohen V, Khuri FR. Chemoprevention of lung cancer. Curr Opin Pulm Med 2004; 10:279-83.
2. Kurie JM, Lotan R, Lee JJ, Lee JS, Morice RC, Liu DD, Xu XC, Khuri FR, Ro JY, Hittelman WN, Walsh GL, Roth JA, Minna JD, Hong WK. Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-β expression in the bronchial epithelium: Results from a randomized placebo-controlled trial. J Natl Cancer Inst 2003; 95:206-14.
3. Khuri FR, Lotan R, Kemp BL, Lippman SM, Wu H, Feng L, Lee JJ, Cooksley CS, Parr B, Chang E, Walsh GL, Lee JS, Hong WK, Xu XC. Retinoic acid receptor-β as a prognostic indicator in stage I nonsmall cell lung cancer. J Clin Oncol 2000; 18:2798-804.
4. Kim YH, Dohi DF, Han GR, Zou CP, Oridate N, Walsh GL, Nesbitt JC, Xu XC, Hong WK, Lotan R. Retinoid refractoriness occurs during lung carcinogenesis despite functional retinoid receptors. Cancer Res 1995; 55:5603-10.
5. Stewart CE, Rotwein P. Growth, differentiation and survival; multiple physiological functions for insulin-like growth factors. Physiol Rev 1996; 76:1005-26.
6. Burroughs KD, Dunn SE, Barrett JC, Taylor JA. Insulin-like growth factor-I: A key regulator of human cancer risk? J Natl Cancer Inst 1999; 91:579-81.
7. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins; biological actions. Endocr Rev 1995; 16:3-34.
8. Baxter RC. Signaling pathways involved in anti-proliferative effects of insulin-like growth factor binding protein-3. J Clin Pathol Mol Pathol 2001; 54:145-8.
9. Kuemmerle JF, Murthy KS, Bowers JG. IGFBP-3 activates TGF-β receptors and directly inhibits growth in human intestinal smooth muscle cells. Am J Physiol Gastrointest Liver Physiol 2004; 287:G795-802.
10. Torrisi R, Pensa F, Orengo MA, Catsafados E, Ponzani P, Boccardo F, Costa A, Decensi A.The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients. Cancer Res 1993; 53:4769-71.
11. Sheikh MS, Shao ZM, Hussain A, Clemmons DR, Chen JC, Roberts Jr CT, LeRoith D, Fontana JA. Regulation of insulin-like growth factor-binding-protein- 1, 2, 3, 4, 5, and 6: Synthesis, secretion, and gene expression in estrogen receptor-negative human breast carcinoma cells. Cell Physiol 1993; 155:556-67.
12. Torrisi R, Parodi S, Fontana V, Pensa F, Casella C, Barreca A, De Palo G, Costa A, Decensi A. Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients. Int J Cancer 1998; 76:787-90.
13. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis. J Natl Cancer Inst 1999; 91:151-6.
14. Chang YS, Wang L, Liu D, Mao L, Hong WK, Khuri FR, Lee HY. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I nonsmall cell lung cancer. Clin Cancer Res 2002; 8:3669-75.
15. Chang YS, Kong G, Sun S, Liu D, El-Naggar AK, Khuri FR, Hong WK, Lee HY. Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I nonsmall cell lung cancer. Clin Cancer Res 2002; 8:3796-802.
16. Lee HY, Chang YS, Han JY, Liu DD, Lee JJ, Lotan R, Spitz MR, Hong WK. Effects of 9-cis-retinoic acid on the insulin-like growth factor axis in former smokers. J Clin Oncol 2005; 23:4439-49.
17. Lippman SM, Sudbo J, Hong WK. Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol 2005; 23:346-56.
18. Sun SY, Wan H, Yue P, Hong WK, Lotan R. Evidence that retinoic acid receptor-β induction by retinoids is important for tumor cell growth inhibition. J Biol Chem 2000; 275:17149-53.
19. Xu XC, Wong WY, Goldberg L, Baer SC, Wolf JE, Ramsdell WM, Alberts DS, Lippman SM, Lotan R. Progressive decreases in nuclear retinoid receptors during skin squamous carcinogenesis. Cancer Res 2001; 61:4306-10.
20. Yan C, Ghaffari M, Whitsett JA, Zeng X, Sever Z, Lin S. Retinoic acid-receptor activation of SP-B gene transcription in respiratory epithelial cells. Am J Physiol 1998; 275:L239-46.
21. Walker GE, Wilson EM, Powell D, Oh Y. Butyrate, a histone deacetylase inhibitor, activates the human IGF binding protein-3 promoter in breast cancer cells: Molecular mechanism involves a Sp1/Sp3 multiprotein complex. Endocrinology 2001; 142:3817-27.
22. Chang YS, Wang L, Suh YA, Mao L, Karpen SJ, Khuri FR, Hong WK, Lee HY. Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in nonsmall-cell lung cancer. Oncogene 2004; 23:6569-80.
23. Suh YA, Lee HY, Virmani A, Wong J, Mann KK, Miller Jr WH, Gazdar A, Kurie JM. Loss of retinoic acid receptor-β gene expression is linked to aberrant histone H3 acetylation in lung cancer cell lines. Cancer Res 2002; 62:3945-9.
24. Albiston AL, Saffery R, Herington AC. Cloning and characterization of the promoter for the rat insulin-like growth factor-binding protein-3 gene. Endocrinology 1995; 136:696-704.
25. Bastien J, Rochette-Egly C. Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene 2004; 328:1-16.
26. de The H, Vivanco-Ruiz MM, Tiollais P, Stunnenberg H, Dejean A. Identification of a retinoic acid responsive element in the retinoic acid receptor-β gene. Nature 1990; 343:177-80.
27. Dupe V, Davenne M, Brocard J, Dolle P, Mark M, Dierich A, Chambon P, Rijli FM. In vivo functional analysis of the Hoxa-1 3V retinoic acid response element (3VRARE). Development 1997; 124:399-410.
28. Qian A, Cai Y, Magee TR, Wan YJ. Identification of retinoic acid-responsive elements on the HNF1-α and HNF4α genes. Biochem Biophys Res Commun 2000; 276:837-42.
29. Bouterfa HL, Piedrafita FJ, Doenecke D, Pfahl M. Regulation of H1(0) gene expression by nuclear receptors through an unusual response element: Implications for regulation of cell proliferation. DNA Cell Biol 1995; 14:909-19.
30. Lin B, Chen GQ, Xiao D, Kolluri SK, Cao X, Su H, Zhang XK. Orphan receptor COUP-TF is required for induction of retinoic acid receptor-β, growth inhibition, and apoptosis by retinoic acid in cancer cells. Mol Cell Biol 2000; 20:957-70.
31. Umesono K, Murakami KK, Thompson CC, Evans RM. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell 1991; 65:1255-66.
32. Kurokawa R, Soderstrom M, Horlein A, Halachmi S, Brown M, Rosenfeld MG, Glass CK. Polarity-specific activities of retinoic acid receptors determined by a corepressor. Nature 1995; 377:451-4.
33. Rastinejad F. Retinoid X receptor and its partners in the nuclear receptor family. Curr Opin Struct Biol 2001; 11:33-8.
34. Xu XC, Sozzi G, Lee JS, Lee JJ, Pastorino U, Pilotti S, Kurie JM, Hong WK, Lotan R. Suppression of retinoic acid receptor beta in nonsmall-cell lung cancer in vivo: Implications for lung cancer development. J Natl Cancer Inst 1997; 89:624-9.
35. Conde I, Paniagua R, Fraile B, Ruiz A, Arenas MI. Expression of vitamin D3 receptor and retinoid receptors in human breast cancer: Identification of potential heterodimeric receptors. Int J Oncol 2004; 25:1183-91.